8-K: NeuroBo Pharmaceuticals Doses First Patient in Phase 1 Obesity Trial, Accelerates Timelines

NeuroBo Pharmaceuticals has dosed the first patient in its Phase 1 clinical trial for DA-1726, a novel dual agonist for obesity treatment, and has accelerated trial timelines.

Summary

• NeuroBo Pharmaceuticals has initiated the Phase 1 clinical trial for DA-1726, a dual agonist targeting both GLP-1 and glucagon receptors for obesity treatment.
• The trial is a two-part study, with the first part being a single ascending dose (SAD) study involving approximately 45 participants, and the second part being a multiple ascending dose (MAD) study with around 36 participants.
• The company has accelerated the trial timelines and now expects top-line data from the SAD part in the third quarter of 2024 and the MAD part in the first quarter of 2025.
• Pre-clinical studies of DA-1726 showed superior weight loss compared to semaglutide (Wegovy) and similar weight reduction to tirzepatide (Zepbound) while consuming more food in mouse models.
• The primary goal of the trial is to assess the safety and tolerability of DA-1726, with secondary endpoints including pharmacokinetics and exploratory endpoints including metabolic and cardiac parameters.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the initiation of the clinical trial, accelerated timelines, and promising pre-clinical data. The company is making good progress in a competitive market.

Positives

• The initiation of the Phase 1 clinical trial for DA-1726 is a significant milestone for the company.
• The accelerated trial timelines suggest efficient progress in the development of DA-1726.
• Pre-clinical data indicates that DA-1726 may have superior weight loss and tolerability compared to existing treatments.
• The dual agonist mechanism of DA-1726 could offer a novel approach to obesity treatment.
• The trial is designed with a randomized, placebo-controlled, double-blind approach, which is considered a robust methodology.

Risks

• The success of the clinical trial is not guaranteed, and results may not align with pre-clinical findings.
• There are risks associated with the development of new pharmaceutical products, including potential adverse events and regulatory hurdles.
• The company's ability to execute its commercial strategy and obtain regulatory approval is subject to various uncertainties.
• The company's financial performance could be impacted by the costs associated with the clinical trial and the license agreement with Dong-A ST Co. Ltd.

Future Outlook

The company anticipates reporting top-line data from the SAD part of the Phase 1 trial in the third quarter of 2024 and from the MAD part in the first quarter of 2025. They also expect to dose the first patient in the MAD part in the third quarter of 2024.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of NeuroBo, stated that dosing the first patient is a groundbreaking achievement and brings DA-1726 closer to treating obesity.
• Management believes DA-1726 may have a better tolerability profile than currently available GLP-1 agonists due to its balanced activation of GLP1R and glucagon receptors.

Industry Context

The announcement is relevant to the broader trend of developing novel treatments for obesity, a significant global health concern. The dual agonist approach of DA-1726 is a competitive area of research, with companies like Eli Lilly and Novo Nordisk also developing similar treatments.

Comparison to Industry Standards

• The document mentions that in pre-clinical mouse models, DA-1726 showed superior weight loss compared to semaglutide (Wegovy), a widely used GLP-1 agonist by Novo Nordisk.
• It also notes that DA-1726 resulted in similar weight reduction while consuming more food compared to tirzepatide (Zepbound), a dual GIP/GLP-1 agonist by Eli Lilly.
• These comparisons suggest that DA-1726 has the potential to be a competitive treatment in the obesity market, pending successful clinical trial results.
• The trial design, with randomized, placebo-controlled, double-blind methodology, aligns with industry standards for clinical trials.

Stakeholder Impact

• Shareholders may view this announcement positively due to the progress in clinical development.
• Employees may be motivated by the advancement of the company's pipeline.
• Patients with obesity may benefit from the potential development of a new treatment option.
• The company's suppliers and partners may see increased activity and potential for future collaborations.

Next Steps

• The company will continue the Phase 1 clinical trial, including the multiple ascending dose (MAD) part.
• Top-line data from the single ascending dose (SAD) part is expected in the third quarter of 2024.
• The first patient in the multiple ascending dose (MAD) part is expected to be dosed in the third quarter of 2024.
• Top-line data from the multiple ascending dose (MAD) part is expected in the first quarter of 2025.

Key Dates

Keywords

DA-1726, obesity, clinical trial, GLP-1 agonist, glucagon receptor, dual agonist, cardiometabolic, Phase 1, weight loss, NeuroBo Pharmaceuticals